PDUFA VII Talks Begin With Similar Goals For Industry, US FDA
Executive Summary
Both sides want enhancements to deal with growth in cell and gene therapy, as well as work on regulatory decision tools and finance issues.
You may also be interested in...
BsUFA III Talks Begin With Regulatory Science Disagreement
Brand trade group negotiators don’t support a biosimilar regulatory science proposal from the biosimilar and generic drug trade groups.
BsUFA III Talks Begin With Regulatory Science Disagreement
Brand trade group negotiators don’t support a biosimilar regulatory science proposal from the biosimilar and generic drug trade groups.
Pandemic Perspectives: NCATS Director Urges Rare Disease Community To Push Against Return To Clinical Trial Status Quo
Chris Austin argued the rare disease community deserves the same “movement of heaven and earth” mentality as was employed for COVID-19.